13D Filing: Longitude Capital Partners, LLC and Corcept Therapeutics Inc (CORT)

Page 2 of 10

Page 2 of 10 – SEC Filing

CUSIP No. 218352102 13D Page 2 of 10 Pages
1

NAMES OF REPORTING PERSONS

Longitude Capital Partners, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a) ¨

(b) ¨

3

SEC USE ONLY

4

SOURCE OF FUNDS (see instructions)

OO1

5

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEM 2(d) or 2(e)

¨

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

1,767,7172

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

1,767,7172

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,767,7172

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES

CERTAIN SHARES (see instructions)

¨

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

1.6%3

14

TYPE OF REPORTING PERSON (see instructions)

OO

1 Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

2 Consists of 1,732,985 shares
of Common Stock held of record by LVP and 34,732 shares of Common Stock held of record by LCA.

3 The percentage was calculated based upon 113,187,462
shares of Common Stock outstanding as of April 28, 2017, as reported by the Issuer in its Quarterly Report on Form 10-Q filed
with the Commission on May 2, 2017.

Follow Corcept Therapeutics Inc (NASDAQ:CORT)

Page 2 of 10